Provided is a microsphere comprising a bead coated with a first calcium-containing mineral. Also provided is a method of producing a microsphere. Additionally, a method of administering a compound to a vertebrate is provided.

The present disclosure relates to the use of silica-forming peptides (SFPs) Volp1 and Salp1 for protein fusion tags for protein purification, silica formation and self-encapsulation, and controlled release of biomolecules. After preparing a fusion protein containing the Volp1 or Salp1 peptide at the C-terminal of the protein, the adsorption conditions for silica (SiO.sub.2) surface were optimized. As a result, a high-purity fusion protein could be purified without an additional tag for purification. The fusion protein containing the silica-forming peptide was self-encapsulated and stably immobilized in the silica matrix through reaction with a silica precursor. The Volp1 and Salp1 peptides showed stronger adsorption ability for silica than the previously known R5 peptide. Using these characteristics, a silica complex wherein two proteins are encapsulated was prepared by mixing the R5 fusion protein with the Volp1 or Salp1 fusion protein. The resulting controlled release system allows the release of the R5 fusion protein in the first step and release of the Salp1 fusion protein in the second step based on the difference in adsorption affinity.

The present invention pertains to the field of nutrition and medicine, and relates to a drug combination for anti-aging and its use. Specifically, the present invention relates to a drug combination comprising: 0.5 to 30 parts by weight of NR or its pharmaceutically acceptable salt, 0.5 to 30 parts by weight of NMN, and 0.01 to 35 parts by weight of mineral. The drug combination of the present invention has good anti-oxidative or anti-aging effects, and has excellent stability.

Disclosed are formulations for providing a therapeutic bioactive polypeptide to injured tissue. Formulations include mineral coated microparticles wherein a polynucleotide is adsorbed to the mineral layer. Other formulations include a carrier including mineral coated microparticles wherein mineral coated microparticles include a polynucleotide. Also disclosed are methods for sustained delivery of a bioactive polypeptide and methods for treating chronic wounds using a formulation for providing sustained delivery of the bioactive peptide.

There is provided a pharmaceutical or veterinary formulation comprising: (a) a plurality of particles having a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 μm, which particles comprise solid cores coated with zinc oxide; suspended in (b) an oleaginous carrier system comprising a pharmaceutically-acceptable or veterinarily-acceptable oil, which zinc oxide coated particles comprise: (1) solid cores comprising a biologically-active agent; (2) one or more discrete layers surrounding said cores, said one or more layers each comprising at least one separate zinc oxide coating. Said zinc oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. When the cores comprise biologically-active agent, and the particles are suspended in an oleaginous carrier system, the formulation may provide for the delayed or sustained release of said active agent without a burst effect.

A method for fabricating an oral drug delivery system includes steps as follows. A mixture is provided, which includes an organic ligand, a metal ion, a biological macromolecule and water. A coating step is performed for forming a biomimetic mineralized carrier encapsulated the biological macromolecule having a surface with the positive charge. A first solution including the biomimetic mineralized carrier is provided. A second solution including a yeast capsule is provided, wherein the yeast capsule has a surface with the negative charge. A loading step is performing, wherein the first solution is mixed with the second solution and then shaken for a shaking time, and the biomimetic mineralized carrier is loaded into the yeast capsule by an electrostatic force to form the oral drug delivery system.

Embodiments disclosed herein relate to magnetic nanoparticles having a non-narcotic analgesic, as well as methods of preparation and use thereof. A magnetically response pharmaceutical can include a core region having magnetic nanoparticles (MNPs) and a protein-based analgesic. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.

Provided herein is a topical combination composition comprising tapinarof, an additional AhR activator and optionally further comprising at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder and exhibit synergistic and/or additive effects which allow reducing the amounts of the active agents in the compositions.

Prokaryotic cells having a metal-phenolic network coating are disclosed, as are compositions including such cells, methods for their use, and methods for producing such cells.

The invention provides compositions and methods that comprise encapsulated silver diamine fluoride or other antimicrobial materials for use in treatment of dental caries, for example.